BBOT to Participate in Upcoming September Investor Healthcare Conferences
BridgeBio Oncology Therapeutics (Nasdaq: BBOT), a clinical-stage biopharmaceutical company specializing in RAS-pathway malignancies, has announced its participation in two major healthcare investor conferences in September 2025.
The company will participate in the Cantor Global Healthcare Conference on September 4 at 8:35 a.m. ET and the Morgan Stanley Global Healthcare Conference on September 8 at 7:45 a.m. ET. Both events will include fireside chats and investor meetings in New York. Webcasts and replays will be accessible through BBOT's investor relations website for 90 days after the events.
BridgeBio Oncology Therapeutics (Nasdaq: BBOT), una societ脿 biofarmaceutica in fase clinica specializzata nelle neoplasie della via RAS, ha annunciato la propria partecipazione a due importanti conferenze per investitori del settore sanitario a settembre 2025.
La societ脿 prender脿 parte alla Cantor Global Healthcare Conference il 4 settembre alle 8:35 ET e alla Morgan Stanley Global Healthcare Conference l'8 settembre alle 7:45 ET. Entrambi gli eventi prevedono incontri con investitori e conversazioni informali (fireside chats) a New York. Webcast e repliche saranno disponibili sul sito investor relations di BBOT per 90 giorni dopo le conferenze.
BridgeBio Oncology Therapeutics (Nasdaq: BBOT), una compa帽铆a biofarmac茅utica en fase cl铆nica especializada en malignidades de la v铆a RAS, ha anunciado su participaci贸n en dos importantes conferencias de inversores del sector salud en septiembre de 2025.
La compa帽铆a asistir谩 a la Cantor Global Healthcare Conference el 4 de septiembre a las 8:35 a.m. ET y a la Morgan Stanley Global Healthcare Conference el 8 de septiembre a las 7:45 a.m. ET. Ambos eventos incluir谩n charlas informales (fireside chats) y reuniones con inversores en Nueva York. Las retransmisiones y grabaciones estar谩n disponibles en la web de relaciones con inversores de BBOT durante 90 d铆as tras los eventos.
BridgeBio Oncology Therapeutics (Nasdaq: BBOT), RAS 瓴诫 鞎旍鞚� 鞝勲鞙茧 頃橂姅 鞛勳儊 雼硠鞚� 氚旍澊鞓れ牅鞎届偓搿滌劀 2025雲� 9鞗旍棎 鞐措Μ電� 霊� 瓯挫潣 欤检殧 項姢旒�鞏� 韴瀽鞛� 旖橅嵓霟办姢鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟.
須岇偓電� 9鞗� 4鞚� 鞓れ爠 8:35(ET)鞐� 鞐措Μ電� Cantor Global Healthcare Conference鞕� 9鞗� 8鞚� 鞓れ爠 7:45(ET)鞐� 鞐措Μ電� Morgan Stanley Global Healthcare Conference鞐� 彀胳劃頃� 鞓堨爼鞛呺媹雼�. 霊� 頄夓偓 氇憪 雺挫殨鞐愳劀 韺岇澊鞏挫偓鞚措摐 毂� 氚� 韴瀽鞛� 氙疙寘鞚� 韽暔頃橂┌, 鞗轨簮鞀ろ姼 氚� 鞛癌靻§潃 頄夓偓 膦呺 頉� 90鞚缄皠 BBOT 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼鞐愳劀 鞁滌箔頃� 靾� 鞛堨姷雼堧嫟.
BridgeBio Oncology Therapeutics (Nasdaq: BBOT), une soci茅t茅 biopharmaceutique en phase clinique sp茅cialis茅e dans les cancers li茅s 脿 la voie RAS, a annonc茅 sa participation 脿 deux grandes conf茅rences pour investisseurs du secteur de la sant茅 en septembre 2025.
La soci茅t茅 participera 脿 la Cantor Global Healthcare Conference le 4 septembre 脿 8h35 ET et 脿 la Morgan Stanley Global Healthcare Conference le 8 septembre 脿 7h45 ET. Les deux 茅v茅nements comprendront des discussions informelles (fireside chats) et des rencontres avec des investisseurs 脿 New York. Les webcasts et les rediffusions seront accessibles sur le site des relations investisseurs de BBOT pendant 90 jours apr猫s les conf茅rences.
BridgeBio Oncology Therapeutics (Nasdaq: BBOT), ein klinisch fortgeschrittenes biopharmazeutisches Unternehmen, das sich auf RAS-Signalwegs-Malignome spezialisiert hat, hat seine Teilnahme an zwei gro脽en Healthcare-Investorenkonferenzen im September 2025 angek眉ndigt.
Das Unternehmen wird an der Cantor Global Healthcare Conference am 4. September um 8:35 Uhr ET sowie an der Morgan Stanley Global Healthcare Conference am 8. September um 7:45 Uhr ET teilnehmen. Beide Events umfassen Fireside-Chats und Investorenmeetings in New York. Webcasts und Wiedergaben sind f眉r 90 Tage nach den Veranstaltungen 眉ber die Investor-Relations-Website von BBOT verf眉gbar.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (鈥淏BOT鈥�) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in two investor conferences in September.
Details of the company鈥檚 participation are as follows:
- Cantor Global Healthcare Conference
- Fireside Chat: Thursday, September 4 at 8:35 a.m. ET as well as hosting investor meetings in New York
- Morgan Stanley Global Healthcare Conference
- Fireside Chat: Monday, September 8 at 7:45 a.m. ET as well as hosting investor meetings in New York
Links for live webcasts and replays, if available, will be available in the on the 鈥淚nvestors鈥� page of the BBOT website. Replays will be available on the website for at least 90 days following the event.
About BBOT
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3K伪 malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit聽 and follow us on .
BBOT Contacts:
Investor Contact:
Uneek Mehra, Chief Financial Officer
BBOT
Media Contact:
Jake Robison
Inizio Evoke Comms
FAQ
When is BBOT presenting at the Cantor Global Healthcare Conference 2025?
When is BBOT's presentation at the Morgan Stanley Global Healthcare Conference 2025?
How can investors access BBOT's conference presentations?
What type of company is BBOT?
